The study and its comparison
A randomized controlled trial enrolled 20,702 participants. Its population was chinese adults with hypertension and no previous stroke or myocardial infarction. The comparison used enalapril 10 mg plus folic acid 0.8 mg versus enalapril alone, with observation over median 4.5 years. [1]
First stroke occurred in 2.7% with the combination and 3.4% with enalapril alone. Myocardial infarction, hemorrhagic stroke and all-cause mortality did not differ significantly. [1]
What the finding establishes
Baseline folate status and the Chinese study setting matter for transferability. This was an addition to an antihypertensive medicine, not a comparison of a B-complex product against treatment. Funding and complete conflicts were not established from the retrieved abstract. [1]
A hypothetical distinction
Imagine 27 versus 34 events per thousand participants over follow-up. The absolute difference is seven per thousand, not a 21-percentage-point reduction.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.